Global Major Depressive Disorder (MDD) Treatment Market

Global Major Depressive Disorder (MDD)
Treatment Market - Size, Share, Growth,
Outlook, and Opportunity Analysis, 2018-2026
Major depressive disorder (MDD) also known as clinical depression is a mental health disorder which
affects mood, behavior as well as appetite and sleep. The exact cause of MDD is not known,
however, several factors which can increase its risk is combination of genes and stress that affects
brain chemistry and reduce the ability to maintain mood stability. Imbalanced hormone, alcohol or
drug abuse, certain medical conditions such as cancer or hypothyroidism, and some adverse effects
of medication such as steroids can also lead to MDD. Changing lifestyles such as work pressure,
alcohol abuse, and others has resulted in increasing prevalence of MDD, which is expected to drive
market growth over the forecast period. For instance, according to an article published in National
Center for Biotechnology Information 2015, MDD is the most common psychiatric disorder in India
and the lifetime prevalence of MDD is 10–25% for women, and 5–12% for men.
Request Sample Copy of Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/1217
Increasing FDA approval for new drugs is expected to drive major depressive disorder
(MDD) treatment market growth in the near future
Major depressive disorder treatment market is witnessing a dynamic change, where patents for
drugs such as Cymbalta and Abilify has expired recently, and revenue generated from these
drugs plummeted with the introduction of generics. Therefore, approval of new drugs such as
Levomilnacipran, Brintellix, and Rexulti (brexpiprazole) is a primary driver for this market growth.
FDA approved levomilnacipran — a new serotonin-norepinephrine reuptake inhibitor (SNRI) — for
major depressive disorder (MDD) in adults in 2013. In the same year, Takeda Pharmaceutical
Company Limited and H. Lundbeck A/S announced the FDA approval for Brintellix (vortioxetine)
for the treatment of adults with major depressive disorder (MDD). Rexulti (brexpiprazole) tablets
received approval from FDA as an add-on treatment to an antidepressant medication to treat
adults with major depressive disorder (MDD) in July, 2015. These approvals are expected to
provide more option to patients suffering from MDD, and this is expected to support the major
depressive disorder treatment market growth.
Report includes chapters which deeply display the following deliverable about industry :
• Global Major Depressive Disorder (MDD) Treatment Market Research Objective and Assumption
• Global Major Depressive Disorder (MDD) Treatment Market Purview - Report Description,
Executive Summary, and Coherent Opportunity Map (COM)
• Global Major Depressive Disorder (MDD) Treatment Market Dynamics, Regulations, and Trends
Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New
system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Global Major Depressive Disorder (MDD) Treatment Market, By Regions
• Global Major Depressive Disorder (MDD) Treatment Market Competition by Manufacturers
including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area
and Product Type.
• Global Major Depressive Disorder (MDD) Treatment Market Manufacturers Profiles/Analysis
including Company Basic Information, Manufacturing Base and Its Competitors.
• Global Major Depressive Disorder (MDD) Treatment Market Manufacturing Cost Analysis including
Key Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning
and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Global Major Depressive Disorder (MDD) Treatment Market Forecast including Production,
Consumption, Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Key players operating in the major depressive disorder treatment market include Eli
Lilly and Company, Allergan, Alkermes, Lundbeck, Johnson & Johnson, Pfizer, Inc.,
AstraZeneca plc, Merck & Co., GlaxoSmithKline plc. Sanofi S.A., and Takeda
Pharmaceutical Company Limited.
Inquire Here Before Purchase:
https://www.coherentmarketinsights.com/insight/talk-to-analyst/1217
Major Depressive Disorder (MDD) Treatment Market Taxonomy
The major depressive disorder (MDD) treatment market is segmented on the basis of product
type and geography
On the basis of product type, major depressive disorder (MDD) treatment market is segmented
into:
• Drug Type
• Antidepressants
• Selective Serotonin Reuptake Inhibitors (SSRIS)
• Lexapro (Escitalopram)
• Viibryd (Vilazodone)
• Dopamine Norepinephrine Reuptake Inhibitor
• Serotonin Norepinephrine Reuptake Inhibitor
• Cymbalta (Duloxetine)
• Effexor (Venlafaxine)
• Fetzima (Levomilnacipran)
• Savella (Milnacipran)
• Pristiq (Desvenlafaxine)
• Serotonin Modulators
• Norepinephrine-Serotonin Modulator
• Tricyclics and Tetracyclics
• Atypical Antidepressants
• Antipsychotics
• Abilify (Aripiprazole)
• Seroquel XR (Quetiapine XR)
• Rexulti (Brexpiprazole)
• Neuromodulators
• Stem Cell Therapy
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Download Report